← FDA DRUG APPROVALS

FDA NDA · NDA019046

NORMOZIDE

Sponsor: SCHERING

APPLICATION
NDA019046
TYPE
NDA
ORIGINAL APPROVAL
1987-04-06
LATEST ACTION
1990-11-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NORMOZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 400MG · TABLET · ORAL
NORMOZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 200MG · TABLET · ORAL
NORMOZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 300MG · TABLET · ORAL
NORMOZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 100MG · TABLET · ORAL

Approval history

1990-11-07Labeling · Supplement 7AP
1989-06-16Labeling · Supplement 6AP
1989-06-16Labeling · Supplement 4AP
1988-04-14Labeling · Supplement 2AP
1987-04-06Type 4 - New Combination · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →